Phathom Pharmaceuticals, Inc. Share Based Compensation of Revenue

Share Based Compensation of Revenue of PHAT for past 10 years: annual, quarterly and twelve month trailing (TTM) including Share Based Compensation of Revenue growth rates and interactive chart.


Highlights and Quick Summary

  • Share Based Compensation of Revenue for the quarter ending September 29, 2021 was 0.0% (a NaN% decrease compared to previous quarter)
  • Year-over-year quarterly Share Based Compensation of Revenue decreased by NaN%
  • Annual Share Based Compensation of Revenue for 2020 was 0.0% (a NaN% decrease from previous year)
  • Annual Share Based Compensation of Revenue for 2019 was 0.0% (a NaN% decrease from previous year)
  • Twelve month Share Based Compensation of Revenue ending September 29, 2021 was 0.0% (a NaN% decrease compared to previous quarter)
  • Twelve month trailing Share Based Compensation of Revenue decreased by NaN% year-over-year
Trailing Share Based Compensation of Revenue for the last four month:
29 Sep '21 29 Jun '21 30 Mar '21 30 Dec '20
0.0% 0.0% 0.0% 0.0%
Visit stockrow.com/PHAT for comprehensive keystats, realtime prices, income statement, balance sheet, cash flow statement with 10 years of data, and state-of-the-art screener.

Historical Share Based Compensation of Revenue of Phathom Pharmaceuticals, Inc.

Most recent Share Based Compensation of Revenueof PHAT including historical data for past 10 years.

Interactive Chart of Share Based Compensation of Revenue of Phathom Pharmaceuticals, Inc.

Phathom Pharmaceuticals, Inc. Share Based Compensation of Revenue for the past 10 Years (both Annual and Quarterly)

Year Q1 Q2 Q3 Q4 Fiscal Year
2021 0.0% 0.0% 0.0%
2020 0.0% 0.0% 0.0% 0.0% 0.0%
2019 0.0% 0.0% 0.0% 0.0%
2018 0.0%

Business Profile of Phathom Pharmaceuticals, Inc.

Sector: Healthcare
Industry: Biotechnology
Phathom Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing treatments for gastrointestinal diseases. The company has the rights in the United States, Europe, and Canada to vonoprazan, a potassium-competitive acid blocker (P-CAB) that blocks acid secretion in the stomach. It is also developing vonoprazan, which is in Phase III clinical trials for the treatment of erosive gastroesophageal reflux disease; and in combination with antibiotics for the treatment of Helicobacter pylori infection. The company was incorporated in 2018 and is headquartered in Florham Park, New Jersey.